Last 12 months
Inside the activity.
5 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 1 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 1 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2022 Filed Mar 31, 2022 20:54 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 610 | $3.93 | $2,397.30 |
DisclosureSEC source: 0001236030-22-000007 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,847 Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 20:52 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 1,091 | $3.93 | $4,287.63 |
DisclosureSEC source: 0001236030-22-000006 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,276 Read SEC document |
| March 31, 2022 Filed Mar 31, 2022 20:49 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 1,106 | $3.93 | $4,346.58 |
DisclosureSEC source: 0001236030-22-000005 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,411 Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 15:14 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 557 | $7.10 | $3,954.70 |
DisclosureSEC source: 0001236030-22-000004 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,078 Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 15:11 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 338 | $7.10 | $2,399.80 |
DisclosureSEC source: 0001236030-22-000003 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,237 Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 15:04 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 612 | $7.10 | $4,345.20 |
DisclosureSEC source: 0001236030-22-000001 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,147,305 Read SEC document |
| December 31, 2021 Filed Jan 3, 2022 15:07 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 604 | $7.10 | $4,288.40 |
DisclosureSEC source: 0001236030-22-000002 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,185 Read SEC document |
| November 19, 2021 Filed Nov 29, 2021 14:33 UTC |
CIPRIANO JOHNSenior Vice President
|
GrantOptions · Derivative | 50,000 | $0.01 Strike: $10.48 | $500.00 |
DisclosureSEC source: 0001236215-21-000015 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 788,827 Underlying: Common Stock · 50,000 shares Expires 2031-11-18 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.48 per share. The stock options vest 100% upon the approval of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. Read SEC document |
| November 19, 2021 Filed Nov 29, 2021 14:29 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantOptions · Derivative | 50,000 | $0.01 Strike: $10.48 | $500.00 |
DisclosureSEC source: 0001236215-21-000014 · primary_doc.xml · derivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,253 Underlying: Common Stock · 50,000 shares Expires 2031-11-18 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.48 per share. The stock options vest 100% upon the approval of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. Read SEC document |
| November 19, 2021 Filed Nov 29, 2021 14:26 UTC |
TALOR EYALChief Scientific Officer
|
GrantOptions · Derivative | 50,000 | $0.01 Strike: $10.48 | $500.00 |
DisclosureSEC source: 0001236215-21-000013 · primary_doc.xml · derivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,463,446 Underlying: Common Stock · 50,000 shares Expires 2031-11-18 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.48 per share. The stock options vest 100% upon the approval of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. Read SEC document |
| November 19, 2021 Filed Nov 29, 2021 14:22 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantOptions · Derivative | 50,000 | $0.01 Strike: $10.48 | $500.00 |
DisclosureSEC source: 0001236215-21-000012 · primary_doc.xml · derivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,403,597 Underlying: Common Stock · 50,000 shares Expires 2031-11-18 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.48 per share. The stock options vest 100% upon the approval of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. Read SEC document |
| November 19, 2021 Filed Nov 29, 2021 14:17 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantOptions · Derivative | 50,000 | $0.01 Strike: $10.48 | $500.00 |
DisclosureSEC source: 0001236215-21-000011 · primary_doc.xml · derivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,781,909 Underlying: Common Stock · 50,000 shares Expires 2031-11-18 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $10.48 per share. The stock options vest 100% upon the approval of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia. None of the options will be exercisable before November 19, 2022. Read SEC document |
| October 19, 2021 Filed Oct 21, 2021 21:24 UTC |
TALOR EYALChief Scientific Officer
|
SaleCommon Stock | 15,000 | $11.25 | $168,750.00 |
DisclosureSEC source: 0001236030-21-000007 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,899 F1 · shares: These shares were sold to pay the taxes due as a result of the milestone reached and subsequent vesting of restricted shares of common stock issued from the 2014 Incentive Stock Bonus Plan. Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 13:11 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 218 | $10.99 | $2,395.82 |
DisclosureSEC source: 0001236030-21-000005 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,899 Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 13:13 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 343 | $10.99 | $3,769.57 |
DisclosureSEC source: 0001236030-21-000006 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,521 Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 13:09 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 372 | $10.99 | $4,088.28 |
DisclosureSEC source: 0001236030-21-000004 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,581 Read SEC document |
| September 30, 2021 Filed Oct 4, 2021 13:07 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 395 | $10.99 | $4,341.05 |
DisclosureSEC source: 0001236030-21-000003 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,146,693 Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 14:51 UTC |
Watson Robert EugeneDirector
|
PurchaseCommon Stock | 1,250 | $8.00 | $10,000.00 |
DisclosureSEC source: 0001646989-21-000008 · primary_doc.xml · nonDerivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,431 Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 14:48 UTC |
BAILLAVOINE BRUNO JEAN-MARIEDirector
|
PurchaseCommon Stock | 1,250 | $8.00 | $10,000.00 |
DisclosureSEC source: 0001646989-21-000007 · primary_doc.xml · nonDerivative · entry 1 BAILLAVOINE BRUNO JEAN-MARIE · CIK 0001646989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,973 Read SEC document |
| July 06, 2021 Filed Jul 7, 2021 14:44 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
PurchaseCommon Stock | 25,000 | $8.00 | $200,000.00 |
DisclosureSEC source: 0001646989-21-000006 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,146,298 F1 · balance_after: Includes 346,421 shares of common stock held by the de Clara Trust. On July 6, 2021, the Company sold 25,000 restricted shares of common stock to the de Clara Trust. Mr. Kersten is a beneficiary of the Trust. Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 13:12 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 435 | $8.68 | $3,775.80 |
DisclosureSEC source: 0001282304-21-000008 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,178 Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 13:08 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 276 | $8.68 | $2,395.68 |
DisclosureSEC source: 0001282304-21-000007 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,681 Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 13:05 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 471 | $8.68 | $4,088.28 |
DisclosureSEC source: 0001282304-21-000006 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,209 Read SEC document |
| June 30, 2021 Filed Jul 1, 2021 13:02 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 501 | $8.68 | $4,348.68 |
DisclosureSEC source: 0001282304-21-000005 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,121,298 Read SEC document |
| June 28, 2021 Filed Jun 29, 2021 14:54 UTC |
YOUNG PETER RDirector
|
PurchaseCommon Stock | 3,000 | $12.66 | $37,971.00 |
DisclosureSEC source: 0001282304-21-000004 · primary_doc.xml · nonDerivative · entry 1 YOUNG PETER R · CIK 0001238029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,914 Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:34 UTC |
Watson Robert EugeneDirector
|
GrantOptions · Derivative | 128,000 | $0.01 Strike: $20.61 | $1,280.00 |
DisclosureSEC source: 0001236215-21-000010 · primary_doc.xml · derivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 506,000 Underlying: Common Stock · 128,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:32 UTC |
BAILLAVOINE BRUNO JEAN-MARIEDirector
|
GrantOptions · Derivative | 128,000 | $0.01 Strike: $20.61 | $1,280.00 |
DisclosureSEC source: 0001236215-21-000009 · primary_doc.xml · derivative · entry 1 BAILLAVOINE BRUNO JEAN-MARIE · CIK 0001646989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 533,500 Underlying: Common Stock · 128,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:29 UTC |
YOUNG PETER RDirector
|
GrantOptions · Derivative | 128,000 | $0.01 Strike: $20.61 | $1,280.00 |
DisclosureSEC source: 0001236215-21-000008 · primary_doc.xml · derivative · entry 1 YOUNG PETER R · CIK 0001238029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 543,100 Underlying: Common Stock · 128,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:26 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantOptions · Derivative | 160,000 | $0.01 Strike: $20.61 | $1,600.00 |
DisclosureSEC source: 0001236215-21-000007 · primary_doc.xml · derivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703,253 Underlying: Common Stock · 160,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:22 UTC |
CIPRIANO JOHNSenior Vice President
|
GrantOptions · Derivative | 130,000 | $0.01 Strike: $20.61 | $1,300.00 |
DisclosureSEC source: 0001236215-21-000006 · primary_doc.xml · derivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 738,827 Underlying: Common Stock · 130,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:18 UTC |
TALOR EYALChief Scientific Officer
|
GrantOptions · Derivative | 318,000 | $0.01 Strike: $20.61 | $3,180.00 |
DisclosureSEC source: 0001236215-21-000005 · primary_doc.xml · derivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,413,446 Underlying: Common Stock · 318,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:14 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantOptions · Derivative | 288,000 | $0.01 Strike: $20.61 | $2,880.00 |
DisclosureSEC source: 0001236215-21-000004 · primary_doc.xml · derivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,353,597 Underlying: Common Stock · 288,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| May 14, 2021 Filed May 17, 2021 21:10 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantOptions · Derivative | 592,000 | $0.01 Strike: $20.61 | $5,920.00 |
DisclosureSEC source: 0001236215-21-000003 · primary_doc.xml · derivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,731,909 Underlying: Common Stock · 592,000 shares Expires 2031-05-13 F1 · derivative.exercise_date: Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022. Read SEC document |
| April 22, 2021 Filed Apr 23, 2021 21:16 UTC |
CIPRIANO JOHNSenior Vice President
|
SaleCommon Stock | 10,000 | $24.38 | $243,793.00 |
DisclosureSEC source: 0001282304-21-000003 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,108 Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 14:13 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 248 | $15.21 | $3,772.08 |
DisclosureSEC source: 0001646989-21-000005 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,743 Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 14:09 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 157 | $15.21 | $2,387.97 |
DisclosureSEC source: 0001646989-21-000004 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,405 Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 14:06 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 269 | $15.21 | $4,091.49 |
DisclosureSEC source: 0001646989-21-000003 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,738 Read SEC document |
| March 31, 2021 Filed Apr 1, 2021 14:03 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 285 | $15.21 | $4,334.85 |
DisclosureSEC source: 0001646989-21-000002 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120,797 Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 14:08 UTC |
TALOR EYALChief Scientific Officer
|
GrantCommon Stock | 205 | $11.66 | $2,390.30 |
DisclosureSEC source: 0001236031-21-000003 · primary_doc.xml · nonDerivative · entry 1 TALOR EYAL · CIK 0001238028 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,248 Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 14:11 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 309 | $11.66 | $3,602.94 |
DisclosureSEC source: 0001236031-21-000004 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,495 Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 14:06 UTC |
PRICHEP PATRICIA BSenior Vice President
|
GrantCommon Stock | 335 | $11.66 | $3,906.10 |
DisclosureSEC source: 0001236031-21-000002 · primary_doc.xml · nonDerivative · entry 1 PRICHEP PATRICIA B · CIK 0001236215 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,469 Read SEC document |
| December 31, 2020 Filed Jan 4, 2021 14:03 UTC |
KERSTEN GEERT RDirector · Chief Executive Officer
|
GrantCommon Stock | 366 | $11.66 | $4,267.56 |
DisclosureSEC source: 0001236031-21-000001 · primary_doc.xml · nonDerivative · entry 1 KERSTEN GEERT R · CIK 0001236030 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,120,512 Read SEC document |
| December 11, 2020 Filed Dec 16, 2020 14:16 UTC |
YOUNG PETER RDirector
|
PurchaseCommon Stock | 100 | $14.24 | $1,424.00 |
DisclosureSEC source: 0001236031-20-000037 · primary_doc.xml · nonDerivative · entry 1 YOUNG PETER R · CIK 0001238029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,914 Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 14:59 UTC |
Watson Robert EugeneDirector
|
PurchaseCommon Stock | 800 | $11.77 | $9,416.00 |
DisclosureSEC source: 0001236031-20-000034 · primary_doc.xml · nonDerivative · entry 1 Watson Robert Eugene · CIK 0001511858 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,181 Read SEC document |
| November 18, 2020 Filed Nov 18, 2020 15:45 UTC |
BAILLAVOINE BRUNO JEAN-MARIEDirector
|
PurchaseCommon Stock | 800 | $11.77 | $9,416.00 |
DisclosureSEC source: 0001236031-20-000035 · primary_doc.xml · nonDerivative · entry 1 BAILLAVOINE BRUNO JEAN-MARIE · CIK 0001646989 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,723 Read SEC document |
| November 17, 2020 Filed Nov 18, 2020 16:10 UTC |
YOUNG PETER RDirector
|
PurchaseCommon Stock | 800 | $11.68 | $9,343.20 |
DisclosureSEC source: 0001236031-20-000036 · primary_doc.xml · nonDerivative · entry 1 YOUNG PETER R · CIK 0001238029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,814 Read SEC document |
| November 13, 2020 Filed Nov 16, 2020 21:49 UTC |
CIPRIANO JOHNSenior Vice President
|
SaleCommon Stock | 10,000 | $12.73 | $127,290.00 |
DisclosureSEC source: 0001236031-20-000033 · primary_doc.xml · nonDerivative · entry 1 CIPRIANO JOHN · CIK 0001282304 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,108 Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:26 UTC |
YOUNG PETER RDirector
|
PurchaseCommon Stock | 2,000 | $11.34 | $22,670.00 |
DisclosureSEC source: 0001236031-20-000032 · primary_doc.xml · nonDerivative · entry 2 YOUNG PETER R · CIK 0001238029 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Immediate Family Disclosed balance after: 25,014 F1 · shares: The shares were purchased by Dr. Young's spouse. Dr. Young disclaims beneficial ownership of these shares. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:26 UTC |
YOUNG PETER RDirector
|
PurchaseCommon Stock | 1,000 | $11.39 | $11,390.00 |
DisclosureSEC source: 0001236031-20-000032 · primary_doc.xml · nonDerivative · entry 1 YOUNG PETER R · CIK 0001238029 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,014 Read SEC document |
| September 30, 2020 Filed Oct 1, 2020 13:40 UTC |
ZIMMERMAN DANIEL HSenior Vice President
|
GrantCommon Stock | 275 | $12.75 | $3,506.25 |
DisclosureSEC source: 0001236031-20-000031 · primary_doc.xml · nonDerivative · entry 1 ZIMMERMAN DANIEL H · CIK 0001236028 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,186 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.